Mentor Capital Cancer Immunotherapy Index Gains 31% During First Half of 2013
SAN DIEGO--(BUSINESS WIRE)-- Mentor Capital, Inc. (Pink Sheets:MNTR) reports that its proprietary Cancer Immunotherapy Index appreciated 30.6% during the first half of 2013. The equally weighted Cancer Immunotherapy Index is regularly benchmarked against the appreciation of the average of the NASDAQ, S&P, and NYSE Biotech Indices. For the first half the biotech indices averaged a 34.5% gain.
Galena (45%), Inovio (59%) and Celldex (133%) have led the sector in gains during the January through June 2013 period. Dendreon ($650 Million), Celldex ($1,262 Million) and NewLink Genetics ($392 Million) represent 66% of the market capitalization of the fifteen member Cancer Immunotherapy Index which has a combined total share value of $3.5 Billion.
The Mentor Capital Cancer Immunotherapy Index companies and their performance for the first twenty-six weeks of 2013 follow: Galena Biopharma Corporation (NASDAQ:GALE) +45.10%, NewLink Genetics Corporation (NASDAQ:NLNK) +22.40%, Vical Incorporated (NASDAQ:VICL) +7.56%, Inovio Pharmaceuticals, Inc. (NYSEMKT:INO) +59.36%, Dendreon (NASDAQ:DNDN) -22.12%, Immunocellular Therapeutics, Ltd. (NYSE MKT:IMUC) +1.04%, Agenus (NASDAQ:AGEN) -7.56%, Oncothyreon (NASDAQ:ONTY) -18.23%, Biovest International (OTCMKTS:BVTIQ) -84.80%, Celldex Therapeutics (NASDAQ:CLDX) +132.64%, Northwest Biotherapeutics (NASDAQ:NWBO) +7.07%, CEL – SCI Corp. (NYSEMKT:CVM) -21.11% , Generex Biotechnology (OTCBB:GNBT) +32.00% as a proxy for its wholly-owned immunotherapeutic subsidiary, Antigen Express, Provectus Pharmaceuticals, Inc. (OTCMKTS:PVCT) +14.29% and Advaxis, Inc. (OTCBB:ADXSD) +34.67% - all for an average 2013 YTD gain of +30.60%. (Annualized rate: +61.20%).
Mentor Capital, Inc., by acquisition or stock purchase, seeks to invest in leading-edge private and public cancer companies, and certain other situations. Mentor created the Cancer Immunotherapy Index July 10, 2009. Since then, it has invested or maintained a tracking position in all companies in the Cancer Immunotherapy Index which can be found at www.MentorCapital.com.
Forward Looking Statements, Safe Harbor and Risk Descriptions are Incorporated by Reference from the MNTR Company Web Site above.
Mentor Capital, Inc.
Chester Billingsley, CEO
(760) 788-4700
Source: Mentor Capital, Inc.
Released July 19, 2013